ASCO, through its Center for Research and Analytics (CENTRA®), has issued a request for research ideas from its members for projects that ASCO could conduct to develop generalizable new knowledge for the oncology community. Of particular need are research ideas that align with the priorities documented in Clinical Cancer Advances 2019: ASCO’s Annual Report on Progress Against Cancer and ASCO’s Strategic Plan or policy priorities. All ideas must be submitted by September 30 using a brief survey.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO, CancerLinQ LLC and its technology collaborator Concerto HealthAI, and data from the practices that participate in the CancerLinQ® platform will be a part of the upcoming “8th Annual Blueprint for Breakthrough Forum—Validating Real-World Endpoints for an Evolving Regulatory Landscape” forum hosted by Friends of Cancer Research on September 18 in Washington, D.C.
New results from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study demonstrate that single-agent palbociclib has no meaningful clinical activity in patients with CDKN2A mutated or deleted advanced pancreatic adenocarcinoma and cholangiocarcinoma.
ASCO recently submitted comments to the Food and Drug Administration (FDA) regarding the agency’s draft guidance recommending specific approaches for sponsors of clinical trials to broaden eligibility criteria, redesign clinical trials, and remove patient barriers to increase enrollment of underrepresented populations in their clinical trials.
ASCO has released an ethical framework for researchers on incorporating research biopsies in cancer clinical trials. The framework, published in a statement in the Journal of Clinical Oncology, provides guidance on when to include optional and mandatory biopsies based on both participant risk and scientific utility.
On July 10, organizations representing patients, providers, medical researchers, survivors, and their families joined together to call on Congress to improve access to clinical trials for patients with life-threatening diseases. The coalition, which is made up of 86 supporting organizations, is urging Congress to pass the bipartisan CLINICAL TREATMENT Act (H.R. 913), which would guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition.
“We applaud the National Academies of Sciences, Engineering, and Medicine for its recommendations on cancer control in the United States. The report examines the oncology community’s efforts over the past 10 years and lays out a comprehensive path for addressing the complex issues facing the entire cancer care continuum, from government agencies to the individual physician.
ASCO’s Center for Research and Analytics (CENTRA) is now accepting research applications from ASCO members who wish to conduct surveys of ASCO members for research purposes.
A new study in the Journal of Oncology Practice (JOP) finds that while primary care physicians (PCPs) are often involved in cancer survivorship care, many do not feel adequately prepared for key components of it.
Positive findings from fully enrolled cohorts in non-small cell lung cancer and metastatic breast cancer from ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR™) Study will be presented in poster sessions at the 2019 ASCO® Annual Meeting. In addition, the study is being expanded to include patients with active brain metastases and three new drug therapies. Pharmaceutical company Boehringer Ingelheim has also joined the study and, later this year, will provide afatinib (Gilotrif®) to participants who enroll in a tissue-agnostic cohort of patients with an NRG1 gene fusion. That same month, the TAPUR Study also will add two new drugs from existing pharmaceutical company collaborators: abemaciclib (Verzenio®, Eli Lilly and Company) and talazoparib (Talzenna®, Pfizer).
ASCO members are encouraged to use the ACT Network to tell their representatives in Congress to support the CLINICAL TREATMENT Act and protect patient access to clinical trials.
A new study published today in the Journal of Oncology Practice (JOP) reveals the findings of a 2018 ASCO Oncology Workforce survey on oncologists’ perceptions and practice behaviors related to diet, physical activity, and weight management in people with cancer — during and after active treatment.
ASCO and the American Cancer Society Cancer Action Network (ACS CAN) hosted a reception on Capitol Hill for Members of Congress and their staff to underscore the two organizations’ shared policy priorities to improve research and cancer care delivery for patients and cancer survivors.
ASCO and Friends of Cancer Research have commended the U.S. Food and Drug Administration on four recently released draft guidance documents related to expanding clinical trial eligibility in a joint letter to Acting Commissioner Ned Sharpless, MD.
Early registration is now open for the ASCO Research Community Forum (RCF) 2019 Annual Meeting. The ASCO RCF Annual Meeting brings together physician investigators and research staff from across the country for two days of learning and collaboration. The meeting offers colleagues from a variety of types of research programs a unique platform to collaborate and develop solutions to common challenges with conducting oncology clinical trials.